Odevixibat
- Generic Name
- Odevixibat
- Brand Names
- Bylvay, 蓓尔唯
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N4O8S2
- CAS Number
- 501692-44-0
- Unique Ingredient Identifier
- 2W150K0UUC
Overview
Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familiar intrahepatic cholestasis (PFIC). Odevixibat is the first approved non-surgical treatment option for PFIC. Previous therapies for PFIC included a bile acid sequestrant such as ursodeoxycholic acid. Odevixibat was granted FDA approval on 20 July 2021.
Background
Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familiar intrahepatic cholestasis (PFIC). Odevixibat is the first approved non-surgical treatment option for PFIC. Previous therapies for PFIC included a bile acid sequestrant such as ursodeoxycholic acid. Odevixibat was granted FDA approval on 20 July 2021.
Indication
Odevixibat is indicated for the treatment of pruritus in patients older than 3 months with progressive familiar intrahepatic cholestasis (PFIC) and cholestatic pruritus in patients 12 months of age and older with Alagille Syndrome. It may not be effective in patients with PFIC type 2 with ABCB11 variants since these patients lack a functional bile salt export pump.
Associated Conditions
- Cholestatic pruritus
- Pruritus
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.